BioVector® GLC-2 人小细胞肺癌细胞株

BioVector® GLC-2 Human Small Cell Lung Carcinoma Cell Line

第一部分 中文说明

一 产品基本信息与遗传学背景

• 细胞名称 BioVector® GLC-2 人小细胞肺癌细胞

• 别名与同义词 GLC 2、GLC2、OC-NYH、NYH

• 系统学 Accession Cellosaurus CVCL_8207

• 物种来源 人类 Homo sapiens

• 组织与疾病背景 该细胞株源自一名小细胞肺癌（SCLC）患者的胸腔积液转移灶。小细胞肺癌属于神经内分泌癌，恶性程度极高且早期极易发生全身广泛转移。

• 突变特征 带有明确的 TP53 基因突变（第8外显子缺失 Ex8del14），常表现出对多种传统拓扑异构酶抑制剂特异性的耐药表型变化。

• 生物安全级别 1级。

二 细胞形态学与培养环境

• 形态学特征 展现典型的小细胞肺癌特征，细胞呈小圆形或短梭形。通常在培养基中呈松散的悬浮细胞团块、聚集体形式生长，胞质极少。

• 神经样分化潜能 在特定药物（如星形孢素 Staurosporine）或特异性细胞外基质成分（如层粘连蛋白 Laminin）的诱导干预下，该悬浮细胞能转变为贴壁并长出长轴突的神经元样（Neuron-like）表型。

• 生长模式 悬浮聚集生长。

• 倍增时间 增殖速度相对温和，倍增时间大约为 37小时。

• 标准完全培养基配方

  • 基础培养基 BioVector® RPMI-1640 培养基。

  • 维持添加 10% 到 15% BioVector® 优质胎牛血清（较高血清浓度有助于维持悬浮细胞簇的活力）。

• 物理培养参数 37摄氏度恒温、5% 二氧化碳、空气饱和湿度。

三 细胞传代与复苏标准操作步骤

1. 常规传代操作

   • 当悬浮的细胞簇生长得过于紧密、庞大，或者培养基显著变黄时需要进行传代。

   • 将包含细胞簇的悬液转移至离心管中，以 150 g 离心 5分钟，弃去旧培养基。

   • 用新鲜的 BioVector® 完全培养基重悬细胞。由于该细胞以细胞簇形式生长，传代时需用移液枪非常轻柔地吹打几下，将极大的团块打散成较小的细胞丛，切勿过度吹打成单细胞，否则会严重阻碍其后续的成活增殖。

   • 传代接种比例通常为 1比2 至 1比3。

2. 冻存细胞复苏

   • 从液氮中取出冷冻管，立即投入 37摄氏度 BioVector® 水浴锅中快速摇动使其融化，控制在 2分钟内。

   • 将解冻的细胞悬液移至含 5 mL 预热培养基的离心管中，以 150 g 离心 5分钟。

   • 弃去含有二甲基亚砜的旧上清，加入新鲜 BioVector® 完全培养基重悬，直接接种到培养瓶内，静置培养。

四 核心科研应用方向

1. 小细胞肺癌（SCLC）靶向耐药机制探索：BioVector® GLC-2 作为原发性小细胞肺癌的典型悬浮模型，广泛用于研究拓扑异构酶 II（Topoisomerase II）催化抑制剂的耐药逃逸机制，以及小细胞肺癌对经典顺铂加依托泊苷方案耐药性的逆转实验。

2. 肿瘤神经内分泌分化与可塑性机制：利用该细胞在细胞外基质（ECM）诱导下向神经元样表型转化的独特性质，用于解析小细胞肺癌在微环境重塑下发生神经分化调控、转录因子网络切换及轴突生长相关的病理机制。

3. 新型肺癌小分子联合用药筛选：用于评估新型细胞周期检查点抑制剂、ROS 诱导剂、多肽偶联药物（PDC）等对高度恶性神经内分泌肺癌细胞株的靶向清除效能。

PART 2 ENGLISH SECTION

I General Information and Genetic Background

• Cell Line Name BioVector® GLC-2

• Synonyms GLC 2, GLC2, OC-Ny, OC-NYH, NYH

• Cellosaurus Accession CVCL_8207

• Species Origin Human Homo sapiens

• Tissue and Disease Background Established from the metastatic pleural effusion sample of a patient suffering from Small Cell Lung Carcinoma (SCLC). SCLC stands as a notoriously aggressive neuroendocrine malignancy characterized by exceptional tumor growth rates and a high propensity for early systemic dissemination.

• Genomic Mutations Houses a validated homozygous TP53 gene deletion mutation (Ex8del14 variant).It is heavily utilized to dissect downstream therapeutic failure following Topoisomerase II catalytic targeting schedules.

• Biosafety Level BSL-1.

II Morphological Attributes and Cultivation Media

• Morphology Exhibits definitive SCLC characteristics including tiny round or short fusiform profiles with minimal cytoplasm. The line proliferates primarily as floating, multi-cellular suspension aggregates and clusters.

• Neuroendocrine Plasticity Upon deliberate exposure to chemical agents like Staurosporine or when cultured on specialized extracellular matrix (ECM) substrates such as Laminin, these suspension cells display phenotypic shifting, adhering firmly and extending long axon-like projections to assume a neuron-like phenotype.

• Growth Mode Suspension growth in clusters.

• Cell Doubling Interval Moderately paced, averaging approximately 37 hours under ideal baselines.

• Standard Complete Growth Medium Formulation

  • Basal Medium BioVector® RPMI-1640 medium.

  • Routine Maintenance Supplements 10% to 15% premium BioVector® Fetal Bovine Serum. Elevated serum parameters cushion suspension cell clustering viability.

• Physical Incubation Thresholds Regulated strictly at 37 degrees Celsius under an atmospheric layer of 5% Carbon Dioxide and saturated air humidity.

III Subculturing and Thawing Protocols

1. Routine Passaging Schedule

   • Subclone the network when the floating aggregates become overly dense, darkened, or when the surrounding media shows an extensive pH color shift to yellow.

   • Collect the cluster suspension into a sterile tube, pellet at 150 g for 5 minutes, and draw off the spent broth.

   • Resuspend the biomaterial in fresh BioVector® complete growth medium. Dissociate large clusters into smaller sub-aggregates by pipetting very gently several times. Do not forcefully shear the cells into absolute single units, as doing so impairs post-passage cell survival.

   • Seed fresh flasks at a recommended split ratio of 1比2 to 1比3.

2. Cryovial Thawing and Recovery

   • Retrieve the cryovial from storage and plunge it into a 37 degrees Celsius BioVector® water bath with immediate agitation until liquefied within 2 minutes.

   • Dilute the suspension into 5 mL of warm medium and spin down at 150 g for 5 minutes.

   • Decant the DMSO tainted supernatant, gently resuspend the remaining cell mass in fresh complete BioVector® medium, and plate directly into a culture vessel for undisturbed incubation.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net